No Picture
News

Forge Enters Into Collaboration With Roche To Develop Novel Antibiotic To Treat Lung Infections

-Forge is eligible to receive $190.5M in total payments-

SAN DIEGO, March 25, 2020 /PRNewswire/ — Forge Therapeutics, Inc. (Forge) announced today that they have entered into a research collaboration and option agreement with Hoffmann-La Roche Ltd. … […]

No Picture
News

Medical Marijuana, Inc. Investment Company AXIM? Biotechnologies Completes Acquisition of Oncology Research and Development Company Sapphire Biotech, Inc.

SAN DIEGO, March 24, 2020 /PRNewswire/ –?Medical Marijuana, Inc.?(OTC: MJNA) (the “Company”), the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands … […]

No Picture
News

NCCN Guidelines Designate Decipher Prostate as “Recommended” for Men with Adverse Pathology after Radical Prostatectomy

The first and only genomic test to achieve “Recommended” status for the management of prostate cancer patients

SAN DIEGO, March 24, 2020 /PRNewswire/ –?Decipher Biosciences, a commercial-stage precision oncology company committed to improving patien… […]

No Picture
News

n-Lorem Foundation receives additional support for providing “n of 1” experimental antisense medicines to treat patients with ultra-rare diseases

CARLSBAD, Calif., March 12, 2020 /PRNewswire/ –?The n-Lorem Foundation announced today it has received an initial pledge of $500,000 from Mark Lampert in support of the n-Lorem Foundation’s efforts to provide advanced, experimental RNA-targeted med… […]

No Picture
News

Denovo Biopharma Announces Breakthrough Discovery of a Novel Genetic Biomarker for DB104 (Liafensine) for Depression

– Potential First Pharmagenomic Biomarker in Neurological Diseases

SAN DIEGO, March 12, 2020 /PRNewswire/ –?Denovo Biopharma LLC, a pioneer in applying precision medicine to develop innovative therapies, today announced it has successfully discovere… […]

No Picture
News

Evofem Biosciences Reports Fourth Quarter and Year-end 2019 Financial Results and Provides Corporate Update

— U.S. Food and Drug Administration (FDA) Grants Conditional Approval for New Brand Name – Phexxi(TM) —- PDUFA Date of May 25, 2020 Assigned for Phexxi New Drug Application (NDA) —- End-of-Phase 2 Meeting Scheduled with FDA to Review Results of th… […]

No Picture
News

Randomized Controlled Trial Results Published in ‘Spine’ Demonstrate Efficacy of NuVasive Attrax® Putty in Posterolateral Lumbar Fusion

– Attrax Putty is now the first and only ceramic bone graft substitute supported by Level I evidence to demonstrate non-inferior fusion performance compared to autograft(1) –

SAN DIEGO, March 10, 2020 /PRNewswire/ –?NuVasive, Inc. (NASDAQ: NUVA), t… […]